Abstract:Background Dry eye disease has a high prevalence and exerts a significant negative effect on quality of life. In China, there are currently no available nasal sprays to promote natural tear production in patients with dry eye disease. We therefore evaluated the efficacy and safety of OC-01 (varenicline solution) nasal spray versus vehicle in Chinese patients with dry eye disease. Methods This was a randomized, multicenter, double -masked, vehicle -controlled, phase 3 clinical trial conducted at ophthalmology departments in 20 hospitals across China (NCT05378945). Eligible patients had a diagnosis of dry eye disease based on patient symptoms, Eye Dryness Score (EDS), Schirmer's Test (with topical anesthesia) Score (STS), and corneal fluorescein staining (CFS) score. Participants were randomly assigned 1:1 using an Interactive Web Response System (IWRS) to receive OC-01 0.6 mg/mL twice daily (BID) or vehicle nasal spray. Participants, investigators, and sponsor were all masked to treatment assignment. The primary endpoint was the percentage of subjects in the intention -to -treat population achieving >= 10 mm improvement in STS from baseline at week 4. Findings In total, 340 patients were randomized from 21 July 2022 to 04 April 2023, 78.8% were female. Patients in the OC-01 group (n = 176) had significantly higher achievement of >= 10 mm improvement in STS (35.8% [n = 63] versus 17.7% [n = 29], stratified odds ratio: 2.67, 95% CI: 1.570-4.533, p = 0.0002) and a significantly greater increase from baseline STS (least -squares mean difference [SE]: 3.87 [0.794], p < 0.0001) at week 4 versus the vehicle group (n = 164). In addition, OC-01 led to a numerically greater reduction in mean EDS from baseline at week 4 compared to the vehicle group (LS mean [SE] difference: -1.3 [2.20]; 95% CI: -5.64 to 2.99, p = 0.5467). The most common adverse event was mild, transient sneezing (78% of OC-01 administrations). No serious adverse events related to nasal administration occurred. Interpretation OC-01 (varenicline solution) nasal spray BID has clinically meaningful efficacy for reducing the signs (as measured by STS) and may improve the symptoms (as measured by EDS) of dry eye disease, with an excellent safety and tolerability profile, in the Chinese population.

Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

Improvement of Social Functioning in Patients with First-Episode Schizophrenia Using Blonanserin Treatment: a Prospective, Multi-Centre, Single-Arm Clinical Trial

Who Can Benefit More from Its Twelve-Week Treatment: A Prospective Cohort Study of Blonanserin for Patients with Schizophrenia

Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial

Population Pharmacokinetics Of Blonanserin In Chinese Healthy Volunteers And The Effect Of The Food Intake

Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.

Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects

The Efficacy and Safety of Sulforaphane As an Adjuvant in the Treatment of Bipolar Depressive Disorder

Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study.

Efficacy and Safety of Blinatumomab in Chinese Adults with Ph-negative Relapsed/refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Multicenter Open-Label Single-Arm China Registrational Study

Efficacy and Safety of Siponimod for Multiple Sclerosis

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials

Varenicline Solution Nasal Spray for Dry Eye Disease in Chinese Patients: a Randomized Phase 3 Trial

The Effectiveness And Safety Of Amisulpride In Chinese Patients With Schizophrenia: An 8-Week, Prospective, Open-Label, Multicenter, Single-Arm Study

Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings

Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

Efficacy and Safety of Rasagiline in Chinese Patients with Early Parkinson’s Disease: a Randomized, Double-Blind, Parallel, Placebo-Controlled, Fixed-Dose Study

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study

Clinical study on Shuxuening combined with antipsychotics in treating chronic schizophreniacombined with antipsychotics in treating chronic schizophrenia

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk